Research Article
A Clinical Monitoring Program of COVID-19 Outpatients: A Prospective Cohort Study
Table 2
Therapeutic agents administered during the study.
| | Administered drugs | n (%) |
| | Statin | 8 (7.6) | | Naproxen | 101 (96.2) | | Hydroxychloroquine | 103 (98.1) | | Azithromycin | 72 (68.6) | | Doxycycline | 33 (31.4) | | Ceftriaxone | 7 (6.7) | | Vitamin D3 | 57 (54.3) | | Zinc | 6 (5.7) | | Pantoprazole | 48 (43.8) | | Diphenhydramine | 99 (94.3) | | Metformin | 5 (4.8) | | ARBs | 10 (9.5) | | Anticoagulants | 6 (5.7) | | Beta blockers | 1 (0.9) | | CCBs | 1 (0.9) |
|
|
ARBs: angiotensin II receptor blockers; CCBs: calcium channel blockers.
|
